Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?
Alkermes plc (NASDAQ:ALKS) reported on September 21 that adults receiving the investigational oral drug ALKS 7290 showed improved symptoms of attention-deficit hyperactivity disorder (ADHD).






